Skip to main content

Aggressive NHL (a NHL) clinical trials at UC Health
1 research study open to new patients

  • Phase 1/2A Dose Escalation Study in CLL, SLL or NHL

    open to eligible people ages 18 years and up

    This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in patients with relapsed/refractory chronic lymphocytic leukemia or non-hodgkin lymphoma

    at UCLA

Last updated: